CPI-0610 is a potent and selective inhibitor of the bromodomain and extra-terminal (BET) family of proteins. It is primarily investigated for its therapeutic potential in oncology, particularly in hematologic malignancies. The compound has shown promising activity in clinical trials for patients with myelofibrosis, a type of myeloproliferative neoplasm. By modulating the expression of key oncogenes such as MYC, CPI-0610 helps reduce disease-related symptoms, improve spleen volume, and enhance overall quality of life. Its mechanism allows for epigenetic regulation of gene transcription without causing direct DNA damage, offering a targeted approach with potentially fewer side effects compared to conventional chemotherapy. Research is ongoing to evaluate its use in combination with other agents like JAK inhibitors to increase efficacy.